Method of treating lung cancer
AssigneeBristol-Myers Squibb Company
InventorMarina Tschaika
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Claims15
A method of treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) comprising administering to the subject an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody”) and an antibody or an antigen-binding portion thereof that binds specifically to Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity (“anti-CTLA-4 antibody”)”), wherein the tumor has ≥5% of tumor cells expressing PD-L1, wherein the anti-PD-1 antibody or antigen-binding portion thereof is administered at a flat dose of about 240 mg, about 360 mg, or about 480 mg once about every 2, 3, or 4 weeks, respectively;
- and wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises nivolumab or pembrolizumab, and the anti-CTLA-4 antibody comprises ipilimumab or tremelimumab.
Dependencies are inferred from the claim text.